The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI’s Brain Cancer Vaccine, Xenon’s Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours:
SVB Leerink Maintains Outperform on Amryt Pharma, Raises Price Target to $18
SVB Leerink analyst Mani Foroohar maintains Amryt Pharma (NASDAQ:AMYT) with a Outperform and raises the price target from $10 to $18.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
55 Biggest Movers From Friday
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate strategic alternatives for the Company to maximize shareholder value.
Amryt Shares Trading Higher As EMA Endorses Approval Of Filsuvez In Genetic Skin Disease
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed the approval of Amryt Pharma Plc’s (NASDAQ:AMYT) Filsuvez…
Amryt Pharma Announces CHMP Adopts Positive Opinion For Filsuvez For The Treatment Of Dystrophic And Junctional EB
CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB
CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB
Positive
Amryt Posts Long-Term Safety, Efficacy Mycapssa Data In Acromegaly Patients
Amryt Pharma Plc (NASDAQ: AMYT) has
Amryt Announces Long-Term Safety And Efficacy Data For Mycapssa From 2nd Year Of OPTIMAL Open Label Extension Study In Acromegaly Patients
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients
Acromegaly patients were exposed to